SCHEMBL8286239

SCHEMBL8286239

CCOC(=O)c1ccc2nc(NC(=O)OC)n(Cc3nc(C)ccc3O)c2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.44
KDM4E B2RXH2 4/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA7 P43166 1/20 0.42
CA9 Q16790 1/20 0.42
CA14 Q9ULX7 1/20 0.42
HSD17B2 P37059 1/20 0.41
PDE2A O00408 2/20 0.40
RAB9A P51151 5/20 0.39
NPC1 O15118 5/20 0.39
SMN1; SMN2 Q16637 4/20 0.39
STAT1 P42224 1/20 0.39
THRB P10828 1/20 0.39
ACSS2 Q9NR19 1/20 0.39
SIRT2 Q8IXJ6 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8286238 0.92 KDM4E (0.47) ALDH1A1KDM4EMEN1KMT2ACA12
SCHEMBL8284700 0.84 CA12 (0.45) ALDH1A1KDM4EMEN1KMT2ACA12
SCHEMBL8294184 0.83 SOS1 (0.44) ALDH1A1KDM4EMEN1KMT2ACA12
SCHEMBL8292653 0.83 DYRK1A (0.41) ALDH1A1KDM4EMEN1KMT2ACA12
SCHEMBL8294222 0.83 KDM4E (0.44) ALDH1A1KDM4EMEN1KMT2ARAB9A
SCHEMBL8294760 0.80 KDM4E (0.43) ALDH1A1KDM4EMEN1KMT2ASIRT2
SCHEMBL8292583 0.80 MC4R (0.47) ALDH1A1KDM4EMEN1KMT2ASIRT2
SCHEMBL8285090 0.79 KDM4E (0.53) ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL8285491 0.79 SSTR5 (0.50) ALDH1A1MEN1KMT2ASMN1; SMN2MAPK1
SCHEMBL8294773 0.79 IDH1 (0.36) ALDH1A1KDM4EMEN1KMT2ACA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8044073-B2 Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication TIBOTEC PHARMACEUTICALS (IE) 2011-10-25 US disclosed
US-8044073-B2 Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication TIBOTEC PHARMACEUTICALS (IE) 2011-10-25 US disclosed
US-20070099924-A1 Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication JANSSEN SCIENCES IRELAND UC (IE) 2007-05-03 US disclosed
US-20070099924-A1 Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication JANSSEN SCIENCES IRELAND UC (IE) 2007-05-03 US disclosed
WO-2005058869-A1 AMINOBENZIMIDAZOLES AND BENZIMIDAZOLES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION TIBOTEC PHARMACEUTICALS LTD. (IE) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099924-A1 Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-2, H1-4 ALDH1A1 1319/4885KDM4E 704/4885MEN1 4025/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.